摘要
用新一代抗组织胺药物阿伐斯丁治疗４５例荨麻疹患者，结果急慢性荨麻疹患者的痊愈率分别为６１．１９％和６４．２８％，患者服药后药物起效迅速，２６．４７％的患者在３０ｍｉｎ内见效，３８．２３％的患者在３０ｍｉｎ～２ｈ内见效。该药无明显中枢抑制等副作用。认为：此药疗效显著，起效快，副反应小，可供临床应用。
patients with urticaria were treated with acrivastine,a new H1 receptor antagonist,by oral,with a cure rate of 61.19%and 64.28%respectively for acute and chronic urticaria。After dosing the onset of action initiated within 30 minutes in 26.47%of patients and between 30 minutes and 2h in 38.23%of patients,and no ob-vious central depression was observed.It can be concluded from the study that the drug is effective and safe with quick onset of action。
出处
《中国新药杂志》
CAS
CSCD
1995年第6期41-42,共2页
Chinese Journal of New Drugs
关键词
荨麻疹
阿伐斯丁
临床疗效
Acrivastine Urticaria Onset of action
